JCO:免疫治疗疗效评价标准imRECIST

2018-07-10 MedSci MedSci原创

美国Dana-Farber癌症研究所Hodi等报告,免疫治疗疗效评价标准(imRECIST)除了通过靶病灶来判断疾病进展(PD)状态外,还通过对无进展生存期(PFS)的评估,以及对疾病进展模式的分析,可以更好地识别出患者在总体生存率上的获益程度。上述结果或可用于修订疗效评价的影像学标准,以便更好地反映肿瘤免疫治疗的疗效。(J Clin Oncol. 2018年1月17日在线版 doi: 10.12

美国Dana-Farber癌症研究所Hodi等报告,免疫治疗疗效评价标准(imRECIST)除了通过靶病灶来判断疾病进展(PD)状态外,还通过对无进展生存期(PFS)的评估,以及对疾病进展模式的分析,可以更好地识别出患者在总体生存率上的获益程度。上述结果或可用于修订疗效评价的影像学标准,以便更好地反映肿瘤免疫治疗的疗效。(J Clin Oncol. 2018年1月17日在线版 doi: 10.1200/JCO.2017.75.1644)

现有评价实体瘤疗效评价标准(RECIST v1.1)不能很好地对实体瘤免疫治疗疗效和总生存进行评价。研究者采用Atezolizumab治疗非小细胞肺癌、转移性尿路上皮癌、肾癌和黑色素瘤患者的临床研究数据,对原评价标准进行修订,允许疾病进展后评价为最佳总体缓解,新病灶和非靶病灶疾病进展定义的改变。

imRECIST标准分析无进展生存,若后续扫描显示疾病控制,则初始疾病进展不计为终点事件。当RECIST v1.1与imRECIST所评估出来的患者(PFS)不一样时,另外评估患者总生存(OS)。

经过这样的修订,imRECIST标准与RECIST v1.1标准相比,患者最佳缓解率提高1%~2%,疾病控制率提高8%~13%,中位PFS延长0.5~1.5个月,延长的PFS与较长或相似的OS相关。imRECIST标准评价,出现新发病灶但靶病灶无进展的患者,其总生存与RECIST v1.1标准评价靶病灶进展的患者相似或稍短。偶尔出现一过性进展(靶病灶进展之后又缩小)的患者OS比没有靶病灶消退患者要长。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
    2019-05-15 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
    2018-07-11 xuyu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
    2018-12-27 freve
  4. [GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
    2018-10-25 cqlidoudou
  5. [GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
    2018-07-12 huagfeg
  8. [GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
    2018-07-11 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

Nature:肿瘤中存在大量与癌症不相关的“吃瓜”杀伤性T细胞,难怪有些患者对免疫治疗没反应

免疫治疗,尤其是免疫检查点抑制剂治疗,可以有效恢复T细胞消灭癌细胞的能力,从而给患者带来显着和持续的临床反应。不过,越来越多的研究证明,仅有一部分患者能从治疗中获益,大部分患者对这种疗法还是不响应。

JAMA Oncol:PD-L1表达可以预测免疫治疗疗效,PD-L1基因扩增呢?

PD-L1表达是目前公认的免疫检查点抑制剂的疗效预测标志物,那么编码PD-L1蛋白的PD-L1基因扩增是否可以预测实体瘤接受免疫治疗的疗效,PD-L1基因扩增在实体瘤中的发生率是多少?近期发布在《JAMA Oncology》杂志的一项研究在大样本量的覆盖多个瘤种的患者队列中采用全面基因组测序,评估PD-L1基因扩增率,以及扩增患者接受免疫治疗的疗效。

肿瘤免疫治疗和提高人体免疫力有没有关系?

问:免疫治疗和提高免疫力有关吗?答:肿瘤免疫治疗主要是就将自身不平衡、失衡的免疫系统纠正过来,而不是说可以无限提升人体的免疫力。免疫肿瘤治疗药物获批,让很多患者看到了新的希望。然而,大众对于免疫治疗存在着误解,也抱着太大的期望。免疫治疗就是癌症的克星?只要用上免疫治疗就一定能“药到病除”?广东省人民医院终身主任吴一龙教授告诉澎湃新闻(www.thepaper.cn),中国人对“免疫”这个词特别敏

Cell Stem Cell:比CAR-T更安全!CAR-NK疗法初显成效

2017年,美国FDA先后批准两款CAR-T细胞疗法,推进了这一代表性免疫疗法的快速发展。除了“小车”CAR(嵌合抗原受体)的选择之外,科学家们开始思考免疫细胞的获得。最新一项研究提出一种可能:利用人类诱导性多能干细胞(iPSCs)获得的自然杀伤细胞(NK)经过类似的修饰之后,同样可以呈现出高效的抗癌活性。

Nat Rev Cancer:溶瘤病毒能怎样协助免疫疗法?

肿瘤免疫疗法在近年来取得了一系列进展,改变了许多癌症的治疗格局。但与此同时,肿瘤免疫疗法也暴露出了作用人群不够广泛等瓶颈,限制了它的应用。为了让其发挥出更大的潜力,研发人员们正在为它寻找帮手,形成更为有效的组合疗法。而在诸多潜在的好帮手中,溶瘤病毒是最为引人关注的新疗法之一。近日,《Nature Reviews | Cancer》刊登了一篇综述,介绍了溶瘤病毒在未来免疫组合疗法中的广阔应用前景。

变应性鼻炎都可以免疫治疗吗?

问:是不是只要是变应性鼻炎就可以免疫治疗呢?答:不是的。过敏性鼻炎,医生也称变应性鼻炎(简称AR),咱老百姓就简称“鼻炎”。是特应性个体接触变应原后由IgE介导的鼻黏膜炎症反应性疾病。简单点来说就是容易过敏的人,接触了导致你过敏的东西后,引起了鼻子的不舒服的反应。这些不舒服的反应主要包括反复喷嚏、流清水样的鼻涕、鼻塞和鼻痒,有时候有眼痒、结膜充血和/或流泪。最新的研究表明过敏性鼻炎在我国大陆地区